A public health approach to the prevention of inhibitors in hemophilia.
作者信息
Soucie J Michael, Miller Connie H, Kelly Fiona M, Oakley Meredith, Brown Deborah L, Kucab Phillip
机构信息
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia.
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, Georgia.
出版信息
Am J Prev Med. 2014 Nov;47(5):669-73. doi: 10.1016/j.amepre.2014.07.007. Epub 2014 Sep 19.
Abstract
The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices.
摘要
相似文献
1
A public health approach to the prevention of inhibitors in hemophilia.
Am J Prev Med. 2014 Nov;47(5):669-73. doi: 10.1016/j.amepre.2014.07.007. Epub 2014 Sep 19.
2
Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.
MMWR Surveill Summ. 2020 Sep 4;69(5):1-18. doi: 10.15585/mmwr.ss6905a1.
3
Public health surveillance and data collection: general principles and impact on hemophilia care.
Hematology. 2012 Apr;17 Suppl 1(0 1):S144-6. doi: 10.1179/102453312X13336169156537.
4
Meeting the emerging public health needs of persons with blood disorders.
Am J Prev Med. 2014 Nov;47(5):658-63. doi: 10.1016/j.amepre.2014.07.008. Epub 2014 Sep 19.
5
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting.
Am J Hematol. 2014 Jun;89(6):621-5. doi: 10.1002/ajh.23704. Epub 2014 Apr 10.
6
Men with severe hemophilia in the United States: birth cohort analysis of a large national database.
Blood. 2016 Jun 16;127(24):3073-81. doi: 10.1182/blood-2015-10-675140. Epub 2016 Mar 16.
7
Evaluation of Knowledge of Patients with Hemophilia Regarding Their Diseases and Treatment in Iran.
Turk J Haematol. 2016 Dec 1;33(4):355-356. doi: 10.4274/tjh.2016.0041. Epub 2016 Jun 17.
8
US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization.
Haemophilia. 2013 Jan;19(1):21-6. doi: 10.1111/j.1365-2516.2012.02915.x. Epub 2012 Jul 30.
9
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia.
Expert Rev Hematol. 2023 Mar;16(sup1):19-37. doi: 10.1080/17474086.2023.2171981.
10
High school completion rates among men with hemophilia.
Am J Prev Med. 2010 Apr;38(4 Suppl):S489-94. doi: 10.1016/j.amepre.2009.12.024.
引用本文的文献
1
The role of public health in rare diseases: hemophilia as an example.
Front Public Health. 2025 Mar 20;13:1450625. doi: 10.3389/fpubh.2025.1450625. eCollection 2025.
2
[Chinese guidelines on the diagnosis and management of hemophilia with inhibitors (2023)].
Zhonghua Xue Ye Xue Za Zhi. 2023 Nov 14;44(11):881-889. doi: 10.3760/cma.j.issn.0253-2727.2023.11.001.
3
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
Haemophilia. 2018 Mar;24(2):186-197. doi: 10.1111/hae.13424. Epub 2018 Feb 15.
4
Improving the performance of factor VIII inhibitor tests in hemophilia A.
Thromb Res. 2015 Dec;136(6):1047-8. doi: 10.1016/j.thromres.2015.09.019. Epub 2015 Sep 28.
5
Blood disorders and public health.
Am J Prev Med. 2014 Nov;47(5):656-7. doi: 10.1016/j.amepre.2014.07.006. Epub 2014 Sep 19.
本文引用的文献
1
A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.
2
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.
J Thromb Haemost. 2013 Sep;11(9):1655-62. doi: 10.1111/jth.12335.
3
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.
4
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3.
5
Allergenic vaccines administration and inhibitor development in haemophilia.
Haemophilia. 2012 Sep;18(5):e392-3. doi: 10.1111/j.1365-2516.2012.02872.x. Epub 2012 Jun 6.
6
Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.
J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.
7
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008.
Haemophilia. 2012 Mar;18(2):276-83. doi: 10.1111/j.1365-2516.2011.02713.x. Epub 2011 Dec 21.
8
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.
Haemophilia. 2012 Mar;18(2):268-75. doi: 10.1111/j.1365-2516.2011.02692.x. Epub 2011 Dec 12.
9
The principal results of the International Immune Tolerance Study: a randomized dose comparison.
Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18.
10
Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.
Blood. 2011 Jun 9;117(23):6367-70. doi: 10.1182/blood-2010-09-308668. Epub 2011 Apr 6.
Zotero 插件